Trial
NCT02065336
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Arrowhead Pharmaceuticals
Collaborators
ICON Clinical Research
Condition
Hepatitis B, Chronic
Intervention
ARC-520
Why stopped
Company decision to discontinue trial
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-13